Vericel Corporation, a biopharmaceutical company focused on advanced therapies, is making waves in the sports medicine and severe burn care markets in the US. With a primary focus on the development, manufacture, and distribution of cellular therapies, Vericel markets an array of autologous cell therapy products that includes MACI and Epicel. The former is a treatment for repairing symptomatic cartilage defects of the knee, while the latter is a permanent skin replacement device used to treat deep-dermal or full-thickness burns in both adults and pediatric patients. The company's preapproval stage candidate, NexoBrid, is a biological orphan product that has shown promise in the eschar removal of adults with deep partial-thickness and/or full-thickness thermal burns. Originally known as Aastrom Biosciences, the Cambridge, Massachusetts-based firm was founded in 1989.
Vericel's ticker is VCEL
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Vericel
It is vcel.com
Vericel is in the Healthcare sector
Vericel is in the Biotechnology industry
The following five companies are Vericel's industry peers: